跳至主要内容
临床试验/NCT01299870
NCT01299870Unknown2 期

Keishibukuryogan (Japanese Herbal Supplement) for the Adjunctive Treatment of Catamenial Epilepsy in Adult: Safety Study

Timothy Welty, PharmD1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
17
试验地点
1
主要终点
To determine if Keishibukuryogan is safe for WWE

研究概览

简要总结

Epilepsy is a disorder in the brain. The brain is full of "nerve" cells. Nerve cells have normal electrical activity to control the many functions of the body. Sometimes nerve cells do not function normally due to many different reasons such as disease, an injury or because the brain didn't develop normally at birth. When nerve cells do not function normally the electrical activity that controls things like muscles and body movement can get mixed up and cause seizures. When a seizure occurs, sometimes a person loses control of body movement, and/or bodily functions. When a seizure occurs, a person may become unconscious, and/or senses may be affected. Seizures can occur at any time, without warning, and can lead to many health problems.

"Catamenial epilepsy" is specific form of epilepsy in women. It is closely related to the menstrual cycle. In this form of epilepsy seizures increase around the menstrual period.

By doing this study, researchers hope to learn whether Keishibukuryogan add-on therapy with antiepileptic drugs is safe for women with epilepsy.

详细描述

It is known that the female hormone levels in epilepsy patients are different from healthy women. These hormonal differences may be part of the cause of catamenial epilepsy. It is estimated that at least 1 in every 3 women with epilepsy have catamenial epilepsy. Although many antiepileptic drugs are available, it is very difficult to control these seizures. In the past, studies using antiepileptic drugs and hormonal agents were done to treat catamenial epilepsy. However, those medications did not work well and caused side effects.

Keishibukuryogan is a traditional Japanese herbal medication. It is made of 5 natural herbs (cinnamon bark, hoelen, moutan bark, peony root, and peach kernel). It is used to treat disorders in women like menopause and menstrual cycle problems. This is the first study to examine the safety of Keishibukuryogan in women with epilepsy. As such, Keishibukuryogan and your current antiepileptic drug(s) will be given to you during the study.

Keishibukuryogan is a dietary supplement in the United States. It can be bought without a prescription. The safety and efficacy of Keishibukuryogan has not been studied in epilepsy. However, it has been used safely in Japan and other Asian countries for years.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
21 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

AED treatment plus placebo

Active Comparator

干预措施: AED treatment plus placebo (Drug)

Keishibukuryogan

Experimental

干预措施: Keishibukuryogan (Drug)

结局指标

主要结局

To determine if Keishibukuryogan is safe for WWE

时间窗: up to 36 weeks

Keishibukuryogan is commonly used in Japan, but has not been formally studied in people with epilepsy. This study is designed to determine if KBG is safe to use in women with epilepsy (no increase of seizure and no adverse reactions).

次要结局

  • To determine if KBG changes seizure frequency in WWE, with a focus on increases in seizure frequency.(up to 36 weeks)
  • To determine if KBG alters progesterone levels in WWE.(up to 36 weeks)

研究者

发起方
Timothy Welty, PharmD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Timothy Welty, PharmD

Professor and Chair of Pharmacy Practice

University of Kansas Medical Center

研究点 (1)

Loading locations...

相似试验